Switch Study of Existing Atypical Antipsychotics to Bifeprunox
NCT ID: NCT00347425
Last Updated: 2008-05-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
286 participants
INTERVENTIONAL
2006-12-31
2008-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
Aripiprazole
Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
Olanzapine
Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
Risperidone
Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
Quetiapine
Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
Ziprasidone
Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
B
Aripiprazole
Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
Olanzapine
Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
Risperidone
Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
Quetiapine
Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
Ziprasidone
Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Aripiprazole
Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
Olanzapine
Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
Risperidone
Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
Quetiapine
Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
Ziprasidone
Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
Aripiprazole
Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
Olanzapine
Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
Risperidone
Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
Quetiapine
Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
Ziprasidone
Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
H. Lundbeck A/S
INDUSTRY
Wyeth is now a wholly owned subsidiary of Pfizer
INDUSTRY
Solvay Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Solvay Pharmaceuticals
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Global Clinical Director Solvay
Role: STUDY_DIRECTOR
Solvay Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site 148
Birmingham, Alabama, United States
Site 194
Little Rock, Arkansas, United States
Site 178
Anaheim, California, United States
Site 167
Cerritos, California, United States
Site 189
Cerritos, California, United States
Site 183
Culver City, California, United States
Site 140
Garden Grove, California, United States
Site 162
La Palma, California, United States
Site 190
Long Beach, California, United States
Site 173
Oceanside, California, United States
Site 175
Paramount, California, United States
Site 136
Pasadena, California, United States
Site 184
Sacramento, California, United States
Site 152
San Diego, California, United States
Site 186
San Diego, California, United States
Site 133
Santa Ana, California, United States
Site 171
Torrance, California, United States
Site 197
Boca Raton, Florida, United States
Site 156
Gainesville, Florida, United States
Site 188
Hialeah, Florida, United States
Site 193
Jacksonville, Florida, United States
Site 154
Miami, Florida, United States
Site 163
North Miami, Florida, United States
Site 168
North Miami, Florida, United States
Site 166
Orange City, Florida, United States
Site 124
Orlando, Florida, United States
Site 187
Tampa, Florida, United States
Site 161
Atlanta, Georgia, United States
Site 128
Augusta, Georgia, United States
Site 122
Decatur, Georgia, United States
Site 174
Chicago, Illinois, United States
Site 164
Indianapolis, Indiana, United States
Site 172
Lake Charles, Louisiana, United States
Site 182
Shreveport, Louisiana, United States
Site 121
Glen Burnie, Maryland, United States
Site 159
Detroit, Michigan, United States
Site 153
Minneapolis, Minnesota, United States
Site 145
Saint Charles, Missouri, United States
Site 130
St Louis, Missouri, United States
Site 141
St Louis, Missouri, United States
Site 142
Clementon, New Jersey, United States
Site 180
Kenilworth, New Jersey, United States
Site 129
Albuquerque, New Mexico, United States
Site 131
Brooklyn, New York, United States
Site 181
Cedarhurst, New York, United States
Site 169
Jamaica, New York, United States
Site 195
New York, New York, United States
Site 147
Staten Island, New York, United States
Site 127
Chagrin Falls, Ohio, United States
Site 176
Cincinnati, Ohio, United States
Site 191
Oklahoma City, Oklahoma, United States
Site 146
Philadelphia, Pennsylvania, United States
Site 179
Philadelphia, Pennsylvania, United States
Site 196
Sioux Falls, South Dakota, United States
Site 134
Memphis, Tennessee, United States
Site 170
Memphis, Tennessee, United States
Site 177
Austin, Texas, United States
Site 185
Conroe, Texas, United States
Site 126
Houston, Texas, United States
Site 151
San Antonio, Texas, United States
Site 138
Richmond, Virginia, United States
Site 198
Spokane, Washington, United States
Site 165
Huntington, West Virginia, United States
Site 302
Buenos Aires, , Argentina
Site 305
Buenos Aires, , Argentina
Site 306
Córdoba, , Argentina
Site 307
La Plata, , Argentina
Site 301
Mendoza, , Argentina
Site 304
Mendoza, , Argentina
Site 308
Mendoza, , Argentina
Site 303
Rosario, , Argentina
Site 116
Chatham, Ontario, Canada
Site 117
Mississauga, Ontario, Canada
Site 100
Calgary, , Canada
Site 101
Claresholm, , Canada
Site 110
Halifax, , Canada
Site 111
Hull, , Canada
Site 107
Kelowna, , Canada
Site 109
Kingston, , Canada
Site 115
Markham, , Canada
Site 112
Medicine Hat, , Canada
Site 108
Orléans, , Canada
Site 106
Ottawa, , Canada
Site 104
Prince Albert, , Canada
Site 102
Sherbrooke, , Canada
Site 114
Victoria, , Canada
Site 113
Winnipeg, , Canada
Site 235
Bolonska, , Czechia
Site 234
Jablonova, , Czechia
Site 216
Litoměřice, , Czechia
Site 233
Na Markvartce, , Czechia
Site 213
Olomouc, , Czechia
Site 214
Pilsen, , Czechia
Site 215
Prague, , Czechia
Site 217
Prague, , Czechia
Site 236
Rejskovo Namesti, , Czechia
Site 231
Paldksi Mnt, , Estonia
Site 229
Tartu, , Estonia
Site 230
Võru, , Estonia
Site 202
Clermont-Ferrand, , France
Site 203
Dole, , France
Site 201
Saint-Cyr-au-Mont-d'Or, , France
Site 206
Balassagyarmat, , Hungary
Site 204
Budapest, , Hungary
Site 205
Budapest, , Hungary
Site 208
Budapest, , Hungary
Site 211
Budapest, , Hungary
Site 207
Debrecen, , Hungary
Site 212
Győr, , Hungary
Site 209
Gyula, , Hungary
Site 210
Pécs, , Hungary
Site 219
Balvi, , Latvia
Site 221
Jelgava, , Latvia
Site 218
Liepāja, , Latvia
Site 222
Riga, , Latvia
Site 220
Sigulda, , Latvia
Site 225
Kaunas, , Lithuania
Site 226
Kaunas, , Lithuania
Site 223
Klaipėda, , Lithuania
Site 232
Šilutė, , Lithuania
Site 224
Vilnius, , Lithuania
Site 228
Vilnius, , Lithuania
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2006-004972-11
Identifier Type: -
Identifier Source: secondary_id
S154.3.020
Identifier Type: -
Identifier Source: org_study_id